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Abstract
Background: Serum response factor (SRF) is crucial for gastric ulcer healing process. The study determined if
gastric ulcer tissues up-regulate SRF and if such up-regulation correlated with co-morbidities and the risk of
recurrent bleeding.
Methods: Ulcer and non-ulcer tissues were obtained from 142 patients with active gastric ulcers for SRF expression
assessed by immunohistochemistry. Based on the degree of SRF expression between these two tissue types, SRF
up-regulation was classified as strong, intermediate, and weak patterns. The patients were followed-up to
determine if SRF up-regulation correlated to recurrent bleeding.
Results: Gastric ulcer tissues had higher SRF expression than non-ulcer tissues (p < 0.05). Patients with strong SRF
up-regulation had lower rates of stigmata of recent hemorrhage (SRH) on the ulcer base than the others (p < 0.05).
Multivariate logistic regression confirmed that co-morbidities and weak SRF up-regulation were two independent
factors of recurrent gastric ulcer bleeding (p < 0.05). Combining both factors, there was an 8.29-fold (95% CI,
1.31~52.62; p = 0.03) higher risk of recurrent gastric ulcer bleeding.
Conclusions: SRF expression is higher in gastric ulcer tissues than in non-ulcer tissues. Weak SRF up-regulation,
combined with the presence of co-morbidities, increase the risk of the recurrent gastric ulcer bleeding.
Background
Peptic ulcer bleeding is a common and potentially
lethal disease with mortality rates as high as 8-10%.
The high mortality is accounted for by senility, etiol-
ogy, severity of bleeding, co-morbidities, and the pre-
sence of stigmata of recent hemorrhage (SRH) [1].
SRH is a classical clinical assessment that predicts the
development of recurrent peptic ulcer bleeding if the
fading time of SRH is 4.1 ± 2.1 days after first bleed
[2,3]. However, patients with co-morbid illnesses are
prone not only to having poor ulcer healing but also
to delayed recurrent bleeding [4-7]. For patients at
risk, it is necessary to validate the possible molecule
mechanisms related to ulcer healing.
Serum Response Factor (SRF), a transcription factor
protein, binds to serum response elements to control
particular genes expressions for peptic ulcer healing
[8-11]. The healing process of gastric ulcers is com-
plex, requiring the restoration and proliferation of
epithelial cells, fibroblasts, macrophages, and endothe-
lial cells [12-15]. SRF reportedly promotes gastric ulcer
healing by stimulating the proliferation and differentia-
tion of such cells [15,16]. Therefore, it is important to
determine the clinical significance of SRF in gastric
ulcers healing, especially in patients with SRH and
co-morbidities.
This study aimed to determine whether SRF expres-
sion in gastric ulcer tissues is higher than that of antral
non-ulcer tissues, and if SRF expression in gastric ulcer
tissues is related to Helicobacter pylori (H. pylori) infec-
tion, non-steroidal anti-inflammatory drugs (NSAID)
intake, or others. This study is the first to validate the
correlation of SRF up-regulation with the presence of
SRH and determine if it is independently predictive of
the recurrent gastric ulcer bleeding.
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Patients and study design
Patients with or without co-morbidities who received
upper gastroscopy for melena, hematochezia, or hema-
temesis and being disclosed gastric ulcers were consecu-
tively enrolled. We enrolled patients with gastric ulcers
but not duodenal ulcers because gastric ulcers biopsy is
performed according to routine practice at the investiga-
tional center. The co-morbidities included congestive
heart failure, coronary artery disease, disseminated
malignancy, liver cirrhosis, acute renal failure, chronic
kidney disease, end-stage renal disease requiring hemo-
dialysis, chronic obstructive pulmonary disease, pneu-
monia, restrictive lung disease, sepsis, and new onset
cerebro-vascular accident.
Patients were excluded if they had tumor bleeding or
ulcer bleeding due to mechanical factors (i.e. induction of
gastrostomy tube), use of anticoagulant, or failure to
establish hemostasis during upper gastroscopy.
The SRH was defined by Forrest et al. [2]. Patients with
bleeding gastric ulcers and classified as Forrest classifica-
tion Ia (arterial bleeding), Ib (oozing bleeding), IIa (non-
bleeding visible vessels), IIb (adherent blood clots), to IIc
(hematin) of gastric ulcers bleeding were treated by stan-
dardized endoscopic injection therapy with diluted
epinephrine 1:10000 or normal saline regardless of com-
bined therapy with heater probe, argon plasma coagula-
tion, band ligation, or hemoclip therapy to eradicate the
vessel. After hemostasis by endoscopic therapy, patients
received an 80 mg bolus injection of intravenous omepra-
zole (LOSEC, AstraZeneca AB, Södertälje, Sweden), then
intravenous omeprazole infusion 8 mg/h for 3 day. After
omeprazole infusion, oral esomeprazole (NEXIUM,
AstraZeneca AB) 40 mg daily was given until the end of
follow-up.
Gastric mucosal biopsies were performed under direct
vision with the Olympus gastroscopy (Olympus GIF-XQ
260 endoscope, Olympus Optical Co. Ltd, Tokyo, Japan)
within 12 h after bleeding. Patients with Forrest classifi-
cation Ia to IIb of gastric ulcers bleeding underwent
second look gastroscopy for gastric mucosal biopsy via
standard biopsy forceps (Olympus FB-25K-1) for histol-
ogy studies three days later. Eight biopsies were taken: six
from the ulcer edge as ulcer tissues and two from the
antral mucosa that was macroscopically normal, about
2c mf r o mt h ep y l o r ir i n ga n da tl e a s t2c mf r o mt h e
ulcer, as antral non-ulcer tissues [17,18].
T h ep a t i e n t sw e r ed i a g n o s e dw i t hH. pylori infection
either by positive rapid urease test (CLO test, Kimberly-
Clark, Draper, Utah, USA) or histology as before [17-19].
NSAID intake was defined as continuous or sporadic
intake more than 3 times a week during the past 4 weeks.
The ethics committee of National Cheng Kung University,
Taiwan, approved the study design and participants pro-
vided informed consent. The institutional review board is
“Pathogenic roles and clinical relevance of TGF-b1a n d
SRF in peptic ulcer patients with comorbid illnesses”.
Outcome measures
All of the patients were followed-up as possible until
28 days after the first episode of melena, hematochezia, or
hematemesis. The primary end-point was recurrent bleed-
ing within this period. Documented recurrent bleeding
should fulfill one of the following conditions: (i) continu-
ous melena, hematochezia, or the presence of recurrent
bloody aspirates through the nasogastric tube; and
(ii) relapse of hemodynamic instability, including systolic
blood pressure <90 mmHg, heart rate >120 beats/min, or
hemoglobin drop >2 g/dL. We did not perform routine
second look endoscopy in the a b s e n c eo fa b o v ec l i n i c a l
signs of re-bleeding to avoid misclassification of non-
significant re-bleeding [20].
Immunohistochemistry Studies for Gastric SRF Expression
Tissue immune-histochemical staining was performed
using monoclonal antibody of SRF (Santa Cruz Biotech-
nology, Inc. Santa Cruz, CA, USA). The gastric tissue was
fixed in 10% buffered formalin. The specimen was
embedded in paraffin, serially sectioned at 4 μmt h i c k n e s s ,
placed onto the microscope slide, and deparaffinized in
xylene and dehydrated in a graded series of ethanol. The
specimen was immersed for 20 minutes in 3% hydrogen
peroxide to stop endogenous peroxidase activity and anti-
gen retrieval with DakoCytomation Target Retrieval Solu-
tion (Dako, Carpinteria, CA, USA). The non-specific
binding site was saturated with 2.5% bovine serum albu-
min. The tissue section was treated with primary antibody
against SRF at a dilution of 1:400 and then incubated over-
night in a humidified chamber at 4°C.
The SuperPicTure™Polymer Detection Kit (Invitrogen,
Carlsbad, CA, USA) was adapted for blocking, linkage, and
labeling for staining according to the manufacturer’s
instructions. 3-amino-9-ethylcarbazole was used as the
chromogen. The section was then counter-stained with
hematoxylin. The colon ulcer tissue was used for positive
control.
The same pathologist blinded to the patients’ clinical
background scored the immune-histochemical staining of
SRF. The expression grades of SRF staining were scored
semi-quantitatively according to the percentage of superfi-
cial epithelial cells or mononuclear cells of the lamina pro-
pria positively stained. The score ranged from 0-4 in
intensity, listed as 0 (negative), 1 (< 5% cells), 2 (5-29%
cells), 3 (30-59% cells), or 4 (≥60% cells) [21,22]. Mucosal
smooth muscle cells were graded as 1 (baseline staining in
capillary muscle), 2 (increase of inter-glandular muscle),
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Page 2 of 8and 3 (increase with nuclear staining) (Figure 1). A score
≥2 was defined as high SRF expression with >5% cells of
the superficial epithelium and mononuclear cells of the
lamina propria positively stained, or with positively stained
inter-glandular smooth muscle cells. A score <2 was
defined as low SRF expression.
The net increase of SRF intensity between ulcer tissues
and non-ulcer tissues within the same individual was also
compared. The net increase of SRF intensity was calcu-
lated as SRF intensity of the ulcer tissue minus that of
the non-ulcer tissue in the superficial epithelium, mono-
nuclear cells of the lamina propria, and mucosal smooth
muscle cells, respectively. Based on the degree of net
increase of SRF intensity, SRF up-regulation on ulcer tis-
sues was classified into strong, intermediate, and weak
patterns. Strong up-regulation of SRF on ulcer tissues
was defined as a uniform net-positive increase of SRF
intensity over the gastric epithelium, mononuclear cells
and muscle cells. In contrast, weak SRF up-regulation on
ulcer tissues was defined by the presence of two net-
negative increases of SRF intensity compared to non-
ulcer tissues. The other patterns of SRF net changes were
accordingly defined as intermediate up-regulation.
Statistical analysis
The Student t test, Fisher’s exact test, one-way ANOVA
and Pearson c
2 test with McNemar’s correction were
used as appropriate. The Mann-Whitney U test was
applied to assess SRF intensity in the different study
groups. All of the tests were two-tailed, with p <0 . 0 5
taken as significant.
Results
Demographic background of the study patients
From August 2003 to December 2007, 142 patients (58
women and 84 men) with mean age of 66 years and gas-
tric ulcers in the active stage were prospectively conse-
cutively enrolled. Of the 142, 132 (93.0%) patients’
ulcers located on the antrum, others located on the
body. Seventy-eight (54.9%) patients had Forrest classifi-
cation Ia to IIc SRH, and 94.2% (49/52) of Ia to IIb SRH
were treated with endoscopic hemostatic monotherapy
or dual therapy. The etiologies of gastric ulcers included
45 H. pylori-infected ulcers, 30 NSAID-related ulcers, 46
H. pylori-infected and NSAID-related ulcers, and 21
other causes induced ulcers.
Gastric ulcer tissues had higher SRF expression than
non-ulcer tissues
SRF was predominantly stained in nuclei or cytoplasm
of regenerative superficial epithelium and mononuclear
inflammatory cells and myofibroblasts of the lamina
propria (Figure 1A and 1B). SRF was also stained in
nuclei of smooth muscle cells of the muscularis mucosa
and vascular wall (Figure 1C). The rates of high SRF
expression were significantly higher in ulcer tissues
(Figure 1A) than in non-ulcer tissues (Figure 1D),
including the superficial epithelium (54.2% vs.3 0 . 3 % ,
p < 0.01), mononuclear cells of the lamina propria (69%
vs. 58.5%, p = 0.021), and mucosal smooth muscle cells
(80% vs. 68.1%, p = 0.024) (Table 1). Moreover, for both
ulcer and non-ulcer tissues, the rates of high SRF inten-
sity on mucosal smooth muscle cells or mononuclear
cells of the lamina propria were higher than those on
the superficial epithelium (p < 0.01).
Factors related to up-regulation of SRF intensity on
gastric ulcer
Based on the degree of the net increase of SRF intensity,
SRF up-regulation were classified into strong (n = 18),
Figure 1 Representative immune-histochemical staining of SRF
expression. (A) High nuclear and cytoplasmic SRF intensity of
regenerative epithelial cells (arrow), some mononuclear
inflammatory cells and myofibroblasts (arrowhead) of the lamina
propria in gastric ulcer tissues (Magnification × 2400). (B) Increased
nuclear and cytoplasmic SRF intensity of smooth muscle cells
(arrow) between the deep glands (× 1200). (C) Nuclear staining of
SRF in smooth muscle cells of the muscularis mucosa (arrow) and
vascular wall (arrowhead) (× 600). (D) Low SRF intensity in non-ulcer
tissues (× 2400). (E) The positive control of colon ulcer tissues
indicates positive nuclear staining in smooth muscle cells (arrow)
and nerve (arrowhead).
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Page 3 of 8intermediate (n = 83), and weak (n = 41) patterns. The
most impressive finding was that patients with strong
up-regulation of SRF intensity had lower rate of Forrest
classification Ia to IIc SRH than patients with either
intermediate or weak SRF up-regulation (p <0 . 0 5 )a n d
had a trend of less co-morbid illness (p =0 . 1 4 ) .N o n e -
theless, there were no differences in age, ulcer size,
endoscopic hemostatic therapy, mean hemoglobin, plate-
let counts, percentage of hypo-albuminemia <3 g/dL,
and serum creatinine ≥1.5 mg/dL among these patients
with different degrees of SRF up-regulation (p >0 . 0 5 ,
Table 2). However, SRF intensities were similar between
patients with serum albumin <3.0 and those with
≥3.0 g/dL (p > 0.05).
There were no differences in H. pylori infection or
NSAID use among patients with different degrees of
SRF up-regulations (p > 0.05) (Table 2). The rates of
high SRF intensity of gastric ulcers were similar among
patients with H. pylori-infected ulcers, NSAID-related
ulcers, or H. pylori-infected and NSAID-related ulcers
(p > 0.05) (Figure 2).
Weak SRF up-regulation independently related with
recurrent gastric ulcer bleeding
Underlying medical co-morbidity and the presence of
weak SRF up-regulation on ulcer tissues were not only
significant univariate factors (Table 3, p < 0.05) but also
independent risk factors of recurrent bleeding (p <
0.05). Age ≥60 years, H. pylori infection, or NSAID use
were not risk factors of recurrent bleeding (p >0 . 0 5 ) .
The recurrent bleeding rates of gastric ulcers increased
stepwise from 0% in non-co-morbid patients without
weak SRF up-regulation, 1.9% in co-morbid patients
without weak SRF up-regulation to 5.9% in non-co-
morbid patients with weak SRF up-regulation and up to
12.5% in co-morbid patients with weak SRF up-regula-
tion (p = 0.006) (Figure 3). Combining both factors, the
risk of recurrent gastric ulcer bleeding in co-morbid
patients with weak SRF up-regulation increased by 8.29-
fold (95% CI, 1.31~52.62; p = 0.03).
The rates of weak SRF up-regulation on gastric ulcers
increased in a trend of patients with neither recurrent
bleeding nor co-morbidity, without recurrent bleeding
Table 1 Gastric ulcer tissues had higher SRF intensity than non-ulcer tissues
Gastric histology (n = 142) High SRF intensity (n, %) P value
†
Ulcer Non-ulcer
Superficial epithelium 77 (54.2%) 43 (30.3%) <0.01
Mononuclear cells of the lamina propria 98 (69.0%) 83 (58.5%) 0.021
Mucosal smooth muscle cells 112 (80.0%) 96 (68.1%) 0.024
P value <0.01
‡,§ , 0.035¶ <0.01
‡,§ , 0.067¶
†P values indicated the significant difference of the rates of the high SRF intensity on ulcer tissues as compared with antral non-ulcer tissues (by McNemar’s test).
‡Superficial epithelium vs. mononuclear cells of the lamina propria.
§Superficial epithelium vs. mucosal smooth muscle cells. ¶Mononuclear cells of the lamina
propria vs. mucosal smooth muscle cells. SRF: serum response factor.
Table 2 Demographic and clinical parameters correlated with different degrees of SRF up-regulation on gastric ulcers
Up-regulation of SRF Strong
(n = 18)
Intermediate
(n = 83)
Weak
(n = 41)
P
value
†
Female: Male 7 : 11 29 : 54 22 : 19 0.13
Mean age (yr) 62.3 66.4 67.0 0.53
Ulcer characteristics (n)
SRH, Forrest classification Ia to IIc (%) 22.2 61.4 58.5 0.01
Mean ulcer size (cm) 1.51 1.47 1.70 0.65
Endoscopic hemostatic therapy in patients with Forrest classification Ia to IIb SRH (%) 100 91.9 100 0.52
H. pylori infection (%) 61.1 62.7 68.3 0.80
NSAID user (%) 55.6 50.6 58.5 0.70
Comorbidity (%) 33.3 57.8 58.5 0.14
Mean Hb (g/dL)
‡ 10.2 10.0 9.6 0.71
Platelet (mm
3)
‡ 300.4 244.7 247.3 0.24
Serum albumin <3 g/dL (%)
‡ 37.5 26.4 36.0 0.62
Serum Creatinine ≥ 1.5 mg/dL (%)
‡ 20.0 26.3 33.3 0.58
Up-regulation of SRF indicated the distribution of net-positive increase of SRF intensity in ulcer tissues than in non-ulcer tissues of superficial epithelium,
mononuclear cells of the lamina propria, and mucosal smooth muscle cells, respectively. SRF: serum response factor; SRH: stigmata of recent hemorrhage;
H. pylori: Helicobacter pylori; NSAID: non-steroidal anti-inflammatory drugs; Hb: hemoglobin.
†One-way ANOVA and Pearson c
2 test were used as appropriate.
‡Reference range: Hb level, 13.5-17 g/dL; platelet count; 138.1-353.4 × 10
3/cmm; serum albumin level, 3.5-5 g/dL; serum creatinine, 0.7-1.5 mg/dL.
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out co-morbidity, and with both recurrent bleeding and
co-morbidity (25.4%, 28.4%, 75%, and 100%, respectively;
p = 0.03).
Discussion
Emerging evidences suggest that the incidences of idio-
pathic peptic ulcer are increasing in Eastern and Wes-
tern countries, at 18.8% and 44%, respectively [4,23-25].
Most of these patients (≥70%) have co-morbid illnesses
and half are severe or life-threatening systemic disor-
ders, such as major organ failure and malignancy [4,23].
These patients have higher risks of ulcer recurrence and
bleeding in one-month, 12-month, or 7-year follow-up
[4,5,7,26]. Although the presence of SRH is a good mea-
sure for predicting recurrent bleeding, it cannot predict
delayed recurrent bleeding in such patients at risk. It is
thus worthy to test whether there is any host back-
ground factor other than SRH that can act as a determi-
nant of recurrent bleeding.
Gastric ulcer healing should be assisted with granulation
tissues developing at the ulcer base, which consist of pro-
liferating fibroblasts and endothelial cells that restore the
lamina propria [12-14,27]. Such healing processes are
related to the expression of immediate early genes (eg,
c-fos) and muscle-specific genes (eg, smooth muscle
a-actin, smoothelin), containing serum response element
(SRE) to be regulated by SRF [28-31]. By comparing
between ulcer tissues and non-ulcer tissues within the
same individual, this study is highly original in revealing
how SRF intensity can be commonly up-regulated in ulcer
tissues than in non-ulcer tissues. Such finding implies that
SRF has a potential role in gastric ulcer healing. However,
because of varying degrees of SRF up-regulation, there is a
need to determine its real clinical significance.
Patients with weak SRF up-regulation in ulcer tissues
have significantly higher rates of Forrest classification Ia
to IIc SRH in gastric ulcers (p <0 . 0 1 )a n dt h i st r e n d
becomes more common with co-morbid illnesses (p =
0.14) (Table 2). Since SRH and co-morbidities carry
higher risks of recurrent bleeding in previous studies
[1,6,19,26,32,33], it will be interesting to determine if
weak SRF up-regulation on ulcer tissues is associated
with recurrent gastric ulcers bleeding.
Aside from serving as significant univariate factors,
both the weak up-regulation of SRF and the presence of
co-morbidity can be independent risk factors for
predicting recurrent gastric ulcer bleeding (p < 0.05)
(Table 3). As both factors can independently determine
recurrent bleeding of gastric ulcers (Table 3), it is not
surprising to show that their combined effect increases
the risk of recurrent gastric ulcer bleeding (Figure 3).
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Figure 2 Percentages of high SRF intensity of gastric ulcers
among patients with different etiologies. The rates of high SRF
intensity of gastric ulcers were similar among patients with H. pylori-
infected ulcers, NSAID-related ulcers, H. pylori-infected and NSAID-
related ulcers, and others, either in the superficial epithelium,
mononuclear cells of the lamina propria, and mucosal smooth
muscle cells (p > 0.05). SRF, serum response factor; H. pylori,
Helicobacter pylori; NSAID, non-steroidal anti-inflammatory drugs.
Table 3 The significant univariate analysis and multivariate logistic regression to determine factors associated with
recurrent bleeding
Related factors
Univariate analysis
Recurrent bleeding rates (%) Odds ratio
(95% CI)
P
value
†
SRH of Forrest classification Ia to IIc vs. none 6.4 vs. 0 - 0.06
Comorbidities vs. none 14.3 vs. 1.7 9.92 (1.55 ~ 63.49) 0.02
Weak up-regulation of SRF vs. others 9.8 vs. 1.0 10.81 (1.17 ~ 99.89) 0.02
Multivariate logistic regression Coefficient (SE) 95% CI P value
‡
Comorbidities vs. none 2.29 (1.05) 1.25 ~ 77.71 0.03
Weak up-regulation of SRF vs. others 2.36 (1.20) 1.02 ~ 111.07 0.048
SRH: stigmata of recent hemorrhage; SRF, serum response factor; CI, Confidence interval; SE, standard error.
†P value was assessed by two-tailed Fisher’s exact
test.
‡Indicated the significance of the multivariate logistic regression.
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our result showed weak SRF up-regulation predisposes to
increased risk of recurrent gastric ulcer bleeding. SRF
makes progress in healing processes such as promotes
migration and proliferation of gastric epithelial cells,
smooth muscle cells, and endothelial cells [15,16]. SRF
deficiency inhibits vascular endothelial growth factor
(VEGF)-stimulated endothelial cell migration and prolif-
eration and inhibits angiogenesis [34]. Further study are
promising to test whether weak SRF up-regulation have a
decreased VEGF expression and poor angiogenesis.
Moreover, it is promising to conduct further study to
validate the correlation between the proliferation index
such as proliferating cell nuclear antigen (PCNA) or Ki-
67 and the SRF expression at the ulcer edge.
SRF is activated by extracellular stimulations such as
serum and mitogens through a ternary complex
factors-dependent pathway involving the ras-raf-mito-
gen-activated protein kinase (MAPK)-extracellular sig-
nal-regulated kinase (ERK) cascade and other pathways
[35]. H. pylori infection activates the SRE-driven c-fos
transcription in epithelial cells through the activation
of ERK/MAPK cascade [36,37]. It is well known that
NSAID suppresses the ERK signaling pathway [38],
however, little is known about the effect of NSAID on
SRE-driven genes transcription. Nevertheless, our
study showed SRF expression on gastric ulcers is not
different between patients with H. pylori infection and
N S A I Du s e r s( F i g u r e2 ) .T h ep o s s i b l er e a s o n sm a yb e
whatever the etiology of gastric ulcers is, SRF is trig-
gered and activated by wounding. As H. pylori infec-
tion and NSAID use are the two major leading
etiologies of gastric ulcers, assessing the up-regulation
of SRF can be widely applied for most patients.
Although co-morbidity remains an important risk factor
of recurrent bleeding of gastric ulcers [1,6,7], the long-
term efficacy of oral proton pump inhibitors (PPI) or
other gastro-protective agents such as misoprostol to pre-
vent ulcer recurrence and bleeding is uncertain. PPI had
been proven to promote gastric epithelial cell proliferation
and migration, and can inhibit pro-inflammatory response,
which is pH-independent [39-41]. Therefore, the SRF role
may be as a possible molecule mechanism and potential
therapeutic target for high-risk patients.
Moreover, the other important issue is who will bene-
fit from such therapy. The risk of recurrent bleeding is
rather low for those without weak SRF up-regulation. In
contrast, the risk increases by 8.29-fold for those with
both co-morbid illnesses and weak up-regulation of SRF
(Figure 3). Data here corroborates the assessment of
SRF expression in gastric ulcer tissues as meaningful
and important in identifying a subset of patients who
carry higher risk of recurrent bleeding. For such
patients, more aggressive bleeding control such as apply-
ing long term oral PPI or improving the weak up-regu-
lation of SRF on gastric ulcers may be mandatory.
Most gastric ulcer bleeding is self-limited, however, a
subset of patients have recurrent bleeding. The prognosis
factors are old age (>60 y/o), comorbidity, large ulcers
(>1.0 cm), SRH, and others [1,2,42,43]. Endoscopic
hemostatic therapy prevents recurrent bleeding and mor-
tality [44]. In order to study the correlation of SRF
expression and co-morbidity, we enrolled patients who
had the similar characteristics of age (70% of patients ≥
60 y/o) and ulcer size (62% of patients had ulcers
≥ 1.0 cm) and almost patients (94.2%) with Forrest classifi-
cation Ia to IIb SRH underwent standardized primary
endoscopic hemostatic therapy. It may be the reasons why
our data show lack of correlation between SRF expression
and age, ulcer size, and endoscopic hemostatic therapy.
Conclusions
In summary, gastric ulcer tissues exert different degrees
of SRF up-regulation. The weak up-regulation of SRF on
ulcer tissues and the presence of co-morbidities inde-
pendently increase the risk of recurrent gastric ulcer
bleeding. Especially in patients with co-morbidities,
improving the up-regulation of SRF may be a potential
therapeutic target for preventing recurrent bleeding.
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